How is testosterone undecanoate injection dosed?
Every vial at a glance.
| Concentration | Draw per dose |
|---|---|
| 250 mg/mL | 250 mg/mL: 250 mg is 1 mL, the 100 mark, 750 mg is over 1 mL, 1,000 mg is over 1 mL |
For adult males with a deficiency or absence of endogenous testosterone, the Aveed label gives 3 mL (750 mg) at the start, after 4 weeks, then every 10 weeks; for male hypogonadism with confirmed deficiency, the Nebido SmPC gives one ampoule or vial (1000 mg testosterone undecanoate) every 10 to 14 weeks.12
Supply, volume and mixing
Aveed is supplied as a 750 mg/3 mL single-use vial at 250 mg/mL.1 The Aveed label's preparation is to inspect the solution and draw 3 mL (750 mg) from the vial; neither label has a step that adds water.1 At the 250 mg/mL both labels give, 750 mg is 3 mL and 1000 mg is 4 mL; the sources give no syringe marks for these volumes.12
Label doses and trial schedules
The Aveed label says to confirm hypogonadism before starting, with serum testosterone measured in the morning on at least 2 separate days and below the normal range, and that dosage titration is not necessary.1 In maintenance, the Nebido SmPC says careful monitoring of serum testosterone is required, measured at the end of an injection interval with clinical symptoms considered, and within the lower third of the normal range; levels below the normal range would indicate a shorter interval, and with high levels an extension of the interval may be considered.2
NCT00467870, an open-label, randomised phase 3 study of 750 mg and 1000 mg doses in hypogonadal men (start date 2006-03, completion 2009-07), enrolled 531 participants, of whom 524 received at least one injection.3
| Trial | People | Dose and schedule | Length |
|---|---|---|---|
| Wang 2010, phase 3 trial4 | 130 men over 18 with serum total T < 300 ng/dL | 750 mg IM at weeks 0 and 4 and every 10 weeks | 9 injections over 84 weeks |
| Minnemann et al. 2008, randomised open-label trial5 | 40 hypogonadal men, 20 per arm; 32 of 40 continued | 1000 mg TU every 6 to 9 weeks, then 1000 mg/12 weeks; comparator 250 mg TE/3 weeks (TE is testosterone enanthate) | 30 weeks, then 114 weeks |
| Nieschlag et al. 1999, open-label non-randomised trial6 | 13 hypogonadal men | 4 IM injections of 1000 mg TU in 4-ml castor oil at 6-week intervals | 24 weeks |
| NCT00467870 Part A, 750 mg arm3 | 120 hypogonadal men started | 750 mg in 3 mL oily solution, IM every 12 weeks | Up to 3 years |
| NCT00467870 Part A, 1000 mg arm3 | 117 hypogonadal men started | 1000 mg in 4 mL oily solution, IM every 12 weeks | Up to 3 years |
| NCT00467870 Part B, 1000 mg arm3 | 112 hypogonadal men started | 1000 mg in 4 mL at baseline, week 8, then every 12 weeks | Up to 24 months |
| NCT00467870 Part C3 | 130 hypogonadal men started | 750 mg in 3 mL at baseline, week 4, then every 10 weeks | Up to 20 months |
| NCT00467870 Part C23 | 23 hypogonadal men started, each at least 65 kg | 750 mg in 3 mL at baseline, week 4, then every 10 weeks | Up to 12 months |
Cycles and stepped dosing
Shankara Narayana et al. (2021), a single-centre prospective surveillance study in Sydney of 326 patients (men with hypogonadism and transmen), gave a first 1000 mg dose, a 1000 mg loading dose at 6 weeks, then injections at initially 12-week intervals.7 After individual titration, the optimal interval (the mean of the last three intervals) had a median of 12.0 weeks (interquartile range 10.4–12.7 weeks) in 297 patients with at least three injections; 23% were at 14 weeks or longer and 7.4% at 10 weeks or shorter.7 Searches of DailyMed, ClinicalTrials.gov and PubMed found no label or trial describing a cycle of testosterone undecanoate; only continuous maintenance schedules are sourced.
Storage
The Aveed label gives storage at controlled room temperature, 25ºC (77ºF), in the original carton, with excursions permitted to 15ºC to 30ºC (59ºF to 86ºF).1 The Nebido SmPC gives a 5-year shelf life, says it must be used immediately after first opening, and says it does not require any special storage conditions.2 It adds that at cold storage temperatures the properties of the oil-based solution might temporarily change (higher viscosity, cloudiness), and that if stored cold the product is brought to room or body temperature before use.2 The Aveed label says to discard any unused portion in the vial, and neither label gives a stability time for a drawn-up or partly used vial.1
Frequently asked questions
Which route and injection site does the Aveed label state?
The Aveed label says it is for intramuscular use only, injected deeply into the gluteus medius muscle in the upper outer quadrant of the buttock, alternating left and right between injections, with patients observed in the healthcare setting for 30 minutes after each injection in case of serious pulmonary oil microembolism (POME) reactions or anaphylaxis.1 The Aveed label also says Aveed is available only through a restricted program called the Aveed REMS Program.1 The Nebido SmPC says it is strictly for intramuscular injection, deeply into the gluteal muscle.2
References
- Endo USA (DailyMed). These highlights do not include all the information needed to use AVEED ® safely and effectively. See full prescribing information for AVEED ® . AVEED ® (testosterone undecanoate) injection, for intramuscular use CIII Initial U.S. Approval: 1953. 2025. dailymed.nlm.nih.gov
- Bayer / electronic medicines compendium. Nebido 1000 mg/4 ml solution for injection - Summary of Product Characteristics (SmPC) - (emc) | 14631. medicines.org.uk
- ClinicalTrials.gov. NCT00467870: Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men. 2017. clinicaltrials.gov
- PubMed. Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial. 2010. pubmed.ncbi.nlm.nih.gov
- PubMed. Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism. 2008. pubmed.ncbi.nlm.nih.gov
- PubMed. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men. 1999. pubmed.ncbi.nlm.nih.gov
- PMC. Optimal injection interval for testosterone undecanoate treatment of hypogonadal and transgender men. 2021. pmc.ncbi.nlm.nih.gov